- Details
- Wei Shen Tan joins Ashish Kamat to discuss the results of the HIVEC-II trial, a randomized controlled trial conducted across the UK that compares patients with adjuvant chemo hyperthermia with mitomycin to passive mitomycin at room temperature in the intermediate-risk non-muscle invasive bladder cancer. Adjuvant intravesical chemotherapy is the recommended standard of care for reducing the risk of...
|
- Details
- In a detailed discussion between Sam Chang and Sarah Psutka, they explore the SunRISe-4 trial, a phase II study investigating the combination of TAR-200 agent with cetrelimab in muscle invasive bladder cancer patients. The trial targets those who are due for radical cystectomy but cannot or refuse the toxic cisplatin-based neoadjuvant chemotherapy, the current standard of care. The study focuses o...
|
- Details
- In this discussion, Ashish Kamat welcomes John Sfakianos. Dr. Sfakianos, recipient of the prestigious BCAN Research Innovation Award, presents his award-winning research on non-muscle invasive bladder cancer and BCG resistance. He delves into the complex interactions within the tumor microenvironment, using novel technologies like spatial transcriptomics to study the diverse roles of various immun...
|
- Details
- Diane Newman welcomes Jeannette Potts to discuss nocturia, a common lower urinary tract symptom characterized by the need to urinate frequently at night. Dr. Potts reveals that this issue, which disrupts sleep and reduces quality of life, affects up to 69% of men and 76% of women. Nocturia may serve as a symptom, a risk factor, or a marker for serious illnesses. Misdiagnosis is a concern, and the...
|
- Details
- Ashish Kamat converses with Patrick Hensley of the University of Kentucky about his 2022 John Quale Travel Award. Dr. Hensley dives deep into his research, which aims to refine patient selection for neoadjuvant chemotherapy for muscle-invasive bladder cancer. His study investigates the predictive capacity of an immunohistochemical (IHC) signature in pre-treatment TURBT specimens. His team's primar...
|
- Details
- Patrick Soon-Shiong joins Ashish Kamat in a discussion on the mechanism of action of N-803 (Anktiva TM ) + BCG Inducing Durable Complete Response in BCG Unresponsive NMIBC. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Dr. Soon-Shiong summarizes the May 2021 phase 1 publication Safety, Tolerability, and Lo...
|
- Details
- Alicia Morgans and Patrick Hensley dive into the complexities surrounding the timing of cystectomy in BCG-unresponsive bladder cancer patients. Dr. Hensley emphasizes the need for a risk-stratified approach, particularly in identifying patients on the BCG failure spectrum, as these patients often present with worse outcomes. Dr. Hensley explains that high-risk patients should receive standard-of-c...
|
- Details
- Anne Schuckman and Alicia Morgans discuss the unique challenges and opportunities for women in urologic oncology. The two explore their own journeys in the field and provide suggestions on how young women seeking a career in urologic oncology can build their careers with confidence. Biographies: Anne K. Schuckman, MD, Director, LAC+USC Urologic Oncology, Keck Hospital of USC, USC Norris Cancer Hos...
|
- Details
- Stephen Williams sits down with Alicia Morgans to share some of the bladder cancer highlights from AUA 2022. Dr. Williams touches on a variety of topics in both muscle-invasive bladder cancer and non-muscle-invasive bladder cancer, including data from the QUILT study at UCLA, a pilot study on a comprehensive geriatric assessment tool at the University of Washington, the importance of psychological...
|
- Details
- Barton Grossman joins Ashish Kamat in highlighting the 25th anniversary of the International Bladder Cancer Network (IBCN). The 2022 meeting is being held again in Barcelona, Spain, from September 29 – October 1. Dr. Grossman shares reflections on the cooperative efforts of the Bladder Cancer Marker Network of the National Cancer Institute (NCI), which focuses on developing and assessing biomarker...
|
